The pharmaceutical industry is complaining about the retroactive application of detailed operation guidelines revised in April at this year's PVA. Although it has already officially proposed excluding retroactive application to the NHIS twice, the NHIS' position is firm.

Analysts say that such an issue will be a hurdle to settle the negotiations at a time when the NHIS entered negotiations with the aim of adjusting drug prices in September. In particular, there are pharmaceutical companies that are expected to suffer billions of won in losses from retroactive use, which is expected to take legal action in the worst case scenario.

According to the industry on the 20th, the industry officia